Biotech company IMV (Quote, Chart TSX:IMV) has reported positive preliminary results from its trial of cancer vaccine DPX-Survivac, reports analyst … [Read more...] about IMV has 48 per cent upside, Mackie Research says
Life Sciences
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Centric Health is a buy, Echelon Wealth says
Centric Health’s (Quote, Chart TSX:CHH) long-term care pharmacy operations are heading in the right direction, says Douglas Loe of Echelon Wealth … [Read more...] about Centric Health is a buy, Echelon Wealth says
IMV Inc. has 50 per cent upside, Mackie Research says
A new development at IMV (Quote, Chart TSX:IMV) has Mackie Research Capital analyst André Uddin maintaining his bullish stance on the stock. This … [Read more...] about IMV Inc. has 50 per cent upside, Mackie Research says
Protech Home Medical has huge upside, Beacon Securities says
Following a quarter that was much better than he expected, Beacon Securities analyst Doug Cooper has raised his price target on Protech Home Medical … [Read more...] about Protech Home Medical has huge upside, Beacon Securities says
Theralase is undervalued, Echelon Wealth Partners says
A new development at Theralase (TSXV:TLT) has Echelon Wealth Partners analyst maintaining his bullish stance on the stock. Theralase today … [Read more...] about Theralase is undervalued, Echelon Wealth Partners says
“Disappointing” Centric Health is still a buy, says Echelon Wealth Partners
Analyst Doug Loe of Echelon Wealth Partners is more cautious about Centric Health (TSX:CHH) after its second quarter financials, announced on Tuesday, … [Read more...] about “Disappointing” Centric Health is still a buy, says Echelon Wealth Partners
Profound Medical Corp. has a potential game-changer on its hands, Paradigm Capital says
Investors may be disappointed with Profound Medical Corp’s (TSX:PRN) second quarter results, but Paradigm Capital analyst Rahul Sarugaser insists that … [Read more...] about Profound Medical Corp. has a potential game-changer on its hands, Paradigm Capital says
Promis Neurosciences has 79 per cent upside, says Mackie Research
After publishing its second quarter results, Canadian biotech company Promis Neurosciences (TSX:PMN) got a target price reduction from André Uddin of … [Read more...] about Promis Neurosciences has 79 per cent upside, says Mackie Research
Viemed Healthcare has 83 per cent upside, Beacon Securities says
Medical equipment supply company Viemed Healthcare (TSX:VMD) posted revenue and EBITDA beats in its second quarter financials, an indication of the … [Read more...] about Viemed Healthcare has 83 per cent upside, Beacon Securities says
Acerus Pharma has huge upside, Mackie Research says
Analyst André Uddin of Mackie Research Capital says the market dynamics in the United States for testosterone replacement therapy are favourable to … [Read more...] about Acerus Pharma has huge upside, Mackie Research says